Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

New instrument automates cancer protein analysis

Cambridge Research And Instrumentation : 24 September, 2008  (New Product)
A new instrument has been demonstrated by a team of scientists led by Cambridge Research and Instrumentation, (CRi), in Woburn, Massachusetts, USA, that makes it possible to detect and quantify multiple clinically important proteins in a single tumour sample using conventional staining.
Currently, pathologists usually need separate tissue slices for each protein they want to examine, making it impossible to see how molecules interact within individual cells.

The new process is fast and automated - up to 180 tumours from different patients can be analysed in an hour - and also provides more information than is available today to help therapy development and direct treatment.

'This technology is designed to be used by pathologists to reveal new data that can help researchers develop targeted therapies, and physicians personalise treatment for individual patients,' said Clifford Hoyt, vice president and chief technical officer at CRi. Hoyt presented the results at the AACR Molecular Diagnostics in Cancer Therapeutic Development meeting being held in Philadelphia, September 22 to 25, 2008.

Researchers say the instrument, which uses multispectral imaging, can detect how many of the cells in a sample of breast cancer display what quantity of any of four different receptors - progesterone receptor (PR), oestrogen receptor (ER), HER1 receptors and HER2 receptors. 'That might show us, for example, that 25 percent of cells express both ER and PR, 50 percent either PR or ER, and 25 percent neither.'

Most pathologists today only stain a sample for a single marker, and two serial sections might show half of the first sample is positive for ER and half of the second sample is positive for PR, Hoyt said. 'You wouldn't know from these serial sections that some cancer cells express both receptors, and that can have implications for treatment. This shows us complex protein expression and interaction patterns in a single tumour section.'

“Even the most advanced microarray-based protein analysis being tested today loses the key molecular phenotype distribution information”, added Hoyt.

Breast cancer markers are just one example of what the instrument can read. 'Pick any four stable proteins found in tissue and we can analyse a cocktail of protein markers all at once,' said Hoyt.

Currently, researchers and pathologists use immunohistochemical staining to examine tumour samples using a Microscope equipped with a colour camera. Colour cameras detect three visible wavelengths, red, green and blue, which mimic the human eye.

The new instrument uses a CRi Nuance multispectral imaging camera, which captures information from multiple wavelengths in the visible and near- infrared, an automated microscope, and novel machine learning-based software to extract data from images. This is an advance over purely visual analysis, or the use of colour cameras, both of which do a poor job disentangling multiple coloured protein labels when they are spatially overlapping.

'Our system looks at samples with 10 to 30 different wavelengths, for staining of up to four proteins using different colours,' Hoyt said. 'With this technique we can unmix multiple different labels from what would otherwise be a muddy mass of colour.'

In this study, the researchers, which included scientists from Novartis Institutes for Biomedical Research and the British Columbia Cancer Agency, stained samples from 356 patients for, ER, PR and HER2 proteins, and then for PR, HER1 and HER2. Results of protein expression using the multispectral imaging were then blindly compared to results from visual assessments by pathologists on samples that were serially stained. According to Hoyt, agreement between the visual and automated analyses was 'the same as we see among pathologists, which is a very good result.'

The analysis shows which proteins are being expressed and the expression level. 'It is a quantitative read-out, so it provides a very specific molecular profile,' Hoyt said.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo